User:Mr. Ibrahem/Tofacitinib

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, and ulcerative colitis. It is used when other treatments are not effective. It is taken by mouth.

Common side effects include diarrhea, headache, and high blood pressure. Serious side effects may include infections, cancer, angioedema, and pulmonary embolism. There are concerns that higher doses may increase the risk of death. Use in pregnancy may harm the baby. It is a janus kinase (JAK) inhibitor.

Tofacitinib was approved for medical use in the United States in 2012 and Europe in 2017. In the United Kingdom it costs the NHS about £690 for 4 weeks of treatment at 5 mg twice per day as of 2021. This amount in the United States costs about 4,600 USD.